Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078

Antiviral Research

Volumn 97, Issue 1, 2013, Pages 60-65

  Portsmouth, Simon ^a   Valluri, Srinivas Rao ^a   Däumer, Martin ^b   Thiele, Bernhard ^b   Valdez, Hernan ^a   Lewis, Marilyn ^c   Craig, Charles ^c   Thielen, Alexander ^d   James, Ian ^c   Demarest, James ^e   Heera, Jayvant ^f  

^a Pf Izer Global Research and Development   (United States)

^b SEQ IT GmbH amp Co KG   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^e VIIV HEALTHCARE   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

ALT; AST; CXCR5; ES; FPR; G2p; Genotype; HIV 1; Maraviroc; MVC; NR; Phenotype; QD; Sff

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CXCR4; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; VIRUS RNA;

ALGORITHM; ARTICLE; ASSAY; CONTROLLED STUDY; FALSE POSITIVE RESULT; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TROFILE ASSAY; VIRUS DETECTION; VIRUS LOAD;

GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTORS, HIV; RNA, VIRAL; VIROLOGY; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871378813     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.11.002     Document Type: Article

References (20)

1. Cooper D.A., Heera J., Goodrich J., Tawadrous M., Saag M., DeJesus E., Clumeck N., Walmsley S., Ting N., Coakley E., Reeves J.D., Reyes-Teran G., Westby M., van der Ryst E., Ive P., Mohapi L., Mingrone H., Horban A., Hackman F., Sullivan J., Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 2010, 201:803-813.
2. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
3. Fätkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H., Hirschel B., Tebas P., Raffi F., Trottier B., Bellos N., Saag M., Cooper D.A., Westby M., Tawadrous M., Sullivan J.F., Ridgway C., Dunne M.W., Felstead S., Mayer H., van der R.E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1442-1455.
4. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
5. Hoffmann C. The epidemiology of HIV coreceptor tropism. Eur. J. Med. Res. 2007, 12:385-390.
6. Hwang S.S., Boyle T.J., Lyerly H.K., Cullen B.R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
7. Jabara C.B., Jones C.D., Roach J., Anderson J.A., Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 2011, 108:20166-20171.
8. Low A.J., Dong W., Chan D., Sing T., Swanstrom R., Jensen M., Pillai S., Good B., Harrigan P.R. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007, 21:F17-F24.
9. McGovern, R.A., Dong, W., Zhong, X., Knapp, D., Thielen, A., Chapman, D., Lewis, M., James, I., Valdez, H., Harrigan, P.R. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay (ESTA) in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial. Poster Presented at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 16-19 February, 2010a.
10. McGovern R.A., Thielen A., Mo T., Dong W., Woods C.K., Chapman D., Lewis M., James I., Heera J., Valdez H., Harrigan P.R. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010, 24:2517-2525.
11. Portsmouth, S., Chapman, D., Lewis, M., Ataher, Q., Greenacre, A., Valdez, V., Harrigan, P.R. Virologic outcome by V3 loop genotypic population sequencing and 454 'deep sequencing' in Clade B and non-B virus in MERIT at 48 and 96 weeks. Poster Presented at the 18th International AIDS Conference, Vienna, Austria, 18-23 July, 2010.
12. Portsmouth, S., Craig, C., Mills, A., Mildvan, D., Podzamczer, D., Fatkenheuer, G., Leal, M., Valdez, H., Valluri, S., Heera, J. 48 week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF)+ATV/r in treatment-naïve (TN) patients infected with CCR5-tropic HIV-1 (Study A4001078). Poster Presented at the IAS, 2011.
13. Poveda E., Seclen E., Gonzalez Mdel M., Garcia F., Chueca N., Aguilera A., Rodriguez J.J., Gonzalez-Lahoz J., Soriano V. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 2009, 63:1006-1010.
14. Reeves J.D., Coakley E., Petropoulos C.J., Whitcomb J.M. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 2009, 3:102.
15. Saliou A., Delobel P., Dubois M., Nicot F., Raymond S., Calvez V., Masquelier B., Izopet J. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob. Agents Chemother. 2011, 55:2831-2836.
16. Sing T., Low A.J., Beerenwinkel N., Sander O., Cheung P.K., Domingues F.S., Buch J., Daumer M., Kaiser R., Lengauer T., Harrigan P.R. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 2007, 12:1097-1106.
17. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Jensen M.A., Thielen A., Chapman D., Lewis M., James I., Heera J., Valdez H., Harrigan P.R. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 2011, 203:237-245.
18. Swenson L.C., Moores A., Low A.J., Thielen A., Dong W., Woods C., Jensen M.A., Wynhoven B., Chan D., Glascock C., Harrigan P.R. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J. Acquir. Immune Defic. Syndr. 2010, 54:506-510.
19. Vandenbroucke I., Van M.H., Mostmans W., Van E., Rondelez E., Thys K., Van B.K., Fransen K., Vaira D., Kabeya K., De W.S., Florence E., Moutschen M., Vandekerckhove L., Verhofstede C., Stuyver L.J. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res. Ther. 2010, 7:4.
20. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L.D., Paxinos E.E., Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 2007, 51:566-575.